The combination of programmed cell death 1/programmed cell death ligand 1 blockade and thoracic radiotherapy has become the new standard of care in the treatment of locally advanced non-small-cell lung cancer. The information regarding the pulmonary safety of such therapy remains limited to mostly retrospective studies and case reports with a small portion of data from prospective clinical trials. By analyzing the underlying mechanisms of interactions between radiation and immunotherapy from preclinical data and summarizing safety data from relevant clinical studies with pulmonary toxicity, we believe that longer and rigorous follow-up is warranted, to determine if the combination of such modalities is appropriate for patients without risking undue toxicity.

程序性细胞死亡1 /程序性细胞死亡配体1阻断与胸腔放疗相结合已成为治疗局部晚期非小细胞肺癌的新治疗标准。关于这种疗法的肺安全性的信息仍然仅限于大多数回顾性研究和病例报告，而前瞻性临床试验的数据却很少。通过从临床前数据分析放射线和免疫疗法之间相互作用的潜在机制，并总结有关肺毒性的相关临床研究的安全性数据，我们认为需要进行更长时间和严格的随访，以确定这些方式的组合是否适合患者不会有过度毒性的风险。